Bradley S Quon1, Darlene L Y Dai2, Zsuzsanna Hollander2, Raymond T Ng3, Scott J Tebbutt4, S F Paul Man1, Pearce G Wilcox1, Don D Sin1. 1. Centre for Heart Lung Innovation, University of British Columbia and St. Paul's Hospital, Vancouver, British Columbia, Canada Division of Respiratory Medicine, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada. 2. PRevention Of Organ Failure (PROOF) Centre of Excellence, Vancouver, British Columbia, Canada. 3. PRevention Of Organ Failure (PROOF) Centre of Excellence, Vancouver, British Columbia, Canada Department of Computer Science, University of British Columbia, Vancouver, British Columbia, Canada. 4. Centre for Heart Lung Innovation, University of British Columbia and St. Paul's Hospital, Vancouver, British Columbia, Canada Division of Respiratory Medicine, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada PRevention Of Organ Failure (PROOF) Centre of Excellence, Vancouver, British Columbia, Canada.
Abstract
BACKGROUND: Despite the significant morbidity and mortality related to pulmonary exacerbations in cystic fibrosis (CF), there remains no reliable predictor of imminent exacerbation. OBJECTIVE: To identify blood-based biomarkers to predict imminent (<4 months from stable blood draw) CF pulmonary exacerbations using targeted proteomics. METHODS: 104 subjects provided plasma samples when clinically stable and were randomly split into discovery (n=70) and replication (n=34) cohorts. Multiple reaction monitoring mass spectrometry (MRM-MS) was used to measure 117 peptides (79 proteins) from plasma. Plasma proteins with differential abundance between subjects who did versus did not develop an imminent exacerbation were analysed and proteins with fold difference >1.5 between the groups were included in an MRM-MS classifier model to predict imminent exacerbations. Performance characteristics were compared with clinical predictors and candidate plasma protein biomarkers. RESULTS: Six proteins were included in the final MRM-MS protein panel. The area under the curve (AUC) for the prediction of imminent exacerbations was highest for the MRM-MS protein panel (AUC 0.74) in comparison to FEV1% predicted (AUC 0.55) and the top candidate plasma protein biomarkers, including C-reactive protein (AUC 0.61) and interleukin-6 (AUC 0.60). The MRM-MS protein panel performed similarly in the replication cohort (AUC 0.73). CONCLUSIONS: Using MRM-MS, a six-protein panel measured from plasma can distinguish individuals with versus without an imminent exacerbation. With further replication and assay development, this biomarker panel may be clinically applicable for prediction of exacerbations in individuals with CF. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
BACKGROUND: Despite the significant morbidity and mortality related to pulmonary exacerbations in cystic fibrosis (CF), there remains no reliable predictor of imminent exacerbation. OBJECTIVE: To identify blood-based biomarkers to predict imminent (<4 months from stable blood draw) CF pulmonary exacerbations using targeted proteomics. METHODS: 104 subjects provided plasma samples when clinically stable and were randomly split into discovery (n=70) and replication (n=34) cohorts. Multiple reaction monitoring mass spectrometry (MRM-MS) was used to measure 117 peptides (79 proteins) from plasma. Plasma proteins with differential abundance between subjects who did versus did not develop an imminent exacerbation were analysed and proteins with fold difference >1.5 between the groups were included in an MRM-MS classifier model to predict imminent exacerbations. Performance characteristics were compared with clinical predictors and candidate plasma protein biomarkers. RESULTS: Six proteins were included in the final MRM-MS protein panel. The area under the curve (AUC) for the prediction of imminent exacerbations was highest for the MRM-MS protein panel (AUC 0.74) in comparison to FEV1% predicted (AUC 0.55) and the top candidate plasma protein biomarkers, including C-reactive protein (AUC 0.61) and interleukin-6 (AUC 0.60). The MRM-MS protein panel performed similarly in the replication cohort (AUC 0.73). CONCLUSIONS: Using MRM-MS, a six-protein panel measured from plasma can distinguish individuals with versus without an imminent exacerbation. With further replication and assay development, this biomarker panel may be clinically applicable for prediction of exacerbations in individuals with CF. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
Authors: Scott D Sagel; Brandie D Wagner; Assem Ziady; Tom Kelley; John P Clancy; Monica Narvaez-Rivas; Joseph Pilewski; Elizabeth Joseloff; Wei Sha; Leila Zelnick; Kenneth D R Setchell; Sonya L Heltshe; Marianne S Muhlebach Journal: J Cyst Fibros Date: 2019-12-20 Impact factor: 5.482
Authors: Marianne S Muhlebach; J P Clancy; Sonya L Heltshe; Assem Ziady; Tom Kelley; Frank Accurso; Joseph Pilewski; Nicole Mayer-Hamblett; Elizabeth Joseloff; Scott D Sagel Journal: J Cyst Fibros Date: 2016-10-27 Impact factor: 5.482
Authors: Hongxiang Mu; Jing Sun; Linwei Li; Jie Yin; Nan Hu; Weichao Zhao; Dexin Ding; Lan Yi Journal: Environ Sci Pollut Res Int Date: 2018-04-29 Impact factor: 4.223
Authors: Laura J Sherrard; Gisli G Einarsson; Elinor Johnston; Katherine O'Neill; Leanne McIlreavey; Stephanie J McGrath; Deirdre F Gilpin; Damian G Downey; Alastair Reid; Noel G McElvaney; Richard C Boucher; Marianne S Muhlebach; J Stuart Elborn; Michael M Tunney Journal: J Cyst Fibros Date: 2019-03-21 Impact factor: 5.482
Authors: Jason Z Cui; Kevin C Harris; Koen Raedschelders; Zsuzsanna Hollander; James E Potts; Astrid De Souza; Marla Kiess; Bruce M McManus; Pascal Bernatchez; Leslie A Raffin; Heidi Paine; Cornelis van Breemen; George G S Sandor; Mitra Esfandiarei Journal: CJC Open Date: 2020-12-28
Authors: Alex H Gifford; Deepika Polineni; Jianghua He; Jessica L D'Amico; Dana B Dorman; Molly A Williams; Amanda B Nymon; Akshu Balwan; Theodore Budden; Jonathan B Zuckerman Journal: Sci Rep Date: 2021-03-01 Impact factor: 4.379
Authors: Janice M Leung; Virginia Chen; Zsuzsanna Hollander; Darlene Dai; Scott J Tebbutt; Shawn D Aaron; Kathy L Vandemheen; Stephen I Rennard; J Mark FitzGerald; Prescott G Woodruff; Stephen C Lazarus; John E Connett; Harvey O Coxson; Bruce Miller; Christoph Borchers; Bruce M McManus; Raymond T Ng; Don D Sin Journal: PLoS One Date: 2016-08-15 Impact factor: 3.240